We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radar. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical ...
Astellas Pharma announces positive topline results from phase 3 EV-304 clinical trial of Padcev plus Keytruda: Tokyo Friday, December 19, 2025, 10:00 Hrs [IST] Astellas Pharma Inc ...
European Space Agency (ESA) astronaut Thomas Pesquet removes the Protein Crystallization Facility hardware from an incubator ...
The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...
While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it ...
Lower prices for first 10 Part D drugs selected for Medicare price negotiations are set to cut seniors' out-of-pocket costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback